



First Quarter 2024 Results

May 2, 2024

enovis™

Creating Better Together™

Forward-looking Statements

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, including the potential benefits of the recently completed acquisition of LimaCorporate S.p.A ("Lima") and other statements that are not historical or current fact. Forward-looking statements and are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks and uncertainties regarding Enovis' and Lima's respective businesses, the effects of the Lima acquisition on Enovis' and Lima's operations, including on the combined company's future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, and business and management strategies for the management, expansion and growth of the new combined company's operations; the potential impact of the consummation of the acquisition on relationships with customer, suppliers and other third parties; the impact of public health emergencies and global pandemics (including COVID-19); escalating geopolitical tensions including in connection with Russia's invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; the impacts of the completed spin-off of ESAB Corporation into an independent publicly traded company (the "Separation"); the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation; the financial and operating performance of the Company following the Separation; other impacts on Enovis' business and ability to execute business continuity plans; and the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Non-GAAP Financial Information

Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin, organic sales growth, pro forma sales and pro forma sales growth. Adjusted net income and adjusted net income per diluted share refer to net income and net income per share, respectively, excluding restructuring and other charges, European Union Medical Device Regulation ("MDR") and other costs, amortization of acquired intangibles, inventory step-up costs, strategic transaction costs, stock compensation costs, other income/expense, and including the tax effect of pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin, which is subject to the same adjustments as adjusted net income. Adjusted EBITDA represents adjusted net income or loss from continuing operations excluding interest, taxes, and depreciation and amortization. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Adjusted gross profit represents gross profit excluding the fair value charges of acquired inventory and the impact of restructuring and other charges. Adjusted gross profit margin is subject to the same adjustments as adjusted gross profit. Pro forma sales adjusts net sales for prior periods to include the sales of acquired businesses (including Lima and Novastep) prior to our ownership from acquisitions that closed after March 31, 2023. Pro forma sales growth represents the change in net sales for the current period compared to pro forma sales for the comparable prior year period. Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions and foreign exchange rate fluctuations. Sales per day growth includes the same adjustments as Organic sales growth and adjusts for the number of selling days in the period. These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this presentation. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

Q1 2024 Highlights




- **+27% reported growth, +5% pro forma**
 - +7% pro forma growth in Recon
 - +3% organic growth in P&R
- **Lima integration off to a great start**
 - Integration plans on track across both commercial and cost initiatives
 - Global recon sales meeting in March formally kicked off cross-selling
- **Expanded adjusted EBITDA margins 220 basis points**
 - Mix benefits from recon growth and the addition of Lima

Off to a good start vs. 2024 Strategic Objectives

Q1 Reconstructive Segment Sales Performance

Reconstructive Q1 Sales

Growth: +66% Y/Y, +7% pro forma



- **Combined performance tracking above plan**
 - +7% pro forma recon growth
 - 2-3% negative growth impact from integration
- **US pro forma growth of 4%**
 - US channel integration in process, expect to be largely complete by end of Q2
 - 8% pro forma Extremities growth led by F&A
 - 0% pro forma Hip/Knee growth vs +22% legacy Enovis in 1Q23
- **International pro forma growth of 10%**
 - Integration efforts going well
- **Encouraging innovation with new products**
 - Altivate Augmented Glenoid launching late 2Q24
 - ARVIS 2.0 Shoulder 510k cleared – initial launch in 2H24

Focused on Lima Integration, off to a solid start in 2024

P&L Performance

<i>millions</i>	<u>Q1 2023</u>	<u>Q1 2024</u>
Net Sales	\$406	\$516
Adj. Gross Profit Margin	\$235 58.0%	\$303 58.7%
Adj. EBITDA Margin	\$56 13.9%	\$83 16.1%
Adj. EPS	\$0.44	\$0.50

- +27% sales growth as reported
- Adjusted gross margin expansion of +70bps driven by product mix and EGX business system
- Continued investments in R&D spend to support key innovation projects
- +220bps of aEBITDA margin expansion driven by Recon mix/Lima, operating leverage and scaling of recent acquisitions

Continue to Expand Margins and Delivered +14% Adjusted EPS growth in Q1

Full Year 2024 Outlook

	February	May	Comments
Revenue	\$2.05-\$2.15B	\$2.06-\$2.16B	<ul style="list-style-type: none"> Global markets grow in line with historical averages <ul style="list-style-type: none"> 5-6% pro forma growth ~HSD pro forma recon growth – weighted to 2H/24 P&R stable in L/MSD Tax rate headwinds from Lima/Pillar 2 ~2 additional selling days in the 2024 4Q aEPS assumes shares of ~56mm
aEBITDA	\$365-\$380mm	\$368-\$383mm	
Depreciation	\$115-\$120mm	\$115-\$120mm	
Interest Expense	\$70-\$75mm	\$70-\$75mm	
Adjusted Tax Rate	~21%	~21%	
aEPS	\$2.50-\$2.65	\$2.52-\$2.67	


Reiterating Expectations for Another Year of Strong Growth and Margin Expansion

Summary



- Excited about the strong start of 2024, underlying growth fundamentals to accelerate in 2H
- Lima integration milestones on track, exciting momentum building globally
- Raising 2024 Guidance based on solid Q1 performance

Appendix



enovis[™]

Creating Better Together™

QTD Pro forma Sales

Enovis Corporation
GAAP and Proforma Net sales
Dollars in millions
(Unaudited)

	Three Months Ended				
	March 29, 2024	March 31, 2023	Growth Rate (GAAP)	March 31, 2023	Growth Rate (Pro forma)
	GAAP			Proforma ⁽¹⁾	
	(In millions)				
Prevention & Recovery:					
U.S. Bracing & Support	104,574	104,375	0.2 %	104,375	0.2 %
U.S. Other P&R	66,350	62,347	6.4 %	62,347	6.4 %
International P&R	88,089	84,018	4.8 %	84,018	4.8 %
Total Prevention & Recovery	<u>259,013</u>	<u>250,740</u>	3.3 %	<u>250,740</u>	3.3 %
Reconstructive:					
U.S. Reconstructive	123,735	103,492	19.6 %	118,903	4.1 %
International Reconstructive	133,518	51,919	157.2 %	121,433	10.0 %
Total Reconstructive	<u>257,253</u>	<u>155,411</u>	65.5 %	<u>240,336</u>	7.0 %
Total	<u>516,266</u>	<u>406,151</u>	27.1 %	<u>491,076</u>	5.1 %

QTD Adjusted EPS Reconciliation

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions, except per share data
(Unaudited)

	Three Months Ended	
	March 29, 2024	March 31, 2023
Adjusted Net Income and Adjusted Net Income Per Share		
Net loss from continuing operations attributable to Enovis Corporation ⁽¹⁾ (GAAP)	\$ (72.0)	\$ (23.0)
Restructuring and other charges - pretax ⁽²⁾	12.9	2.9
MDR and other costs - pretax ⁽³⁾	4.9	7.8
Amortization of acquired intangibles - pretax	40.9	32.0
Inventory step-up - pretax	5.1	0.1
Strategic transaction costs - pretax ⁽⁴⁾	20.8	11.6
Stock-based compensation	6.4	6.9
Other (income) expense, net	24.2	(0.7)
Tax adjustment ⁽⁵⁾	\$ (15.6)	(13.6)
Adjusted net income from continuing operations (non-GAAP)	<u>\$ 27.7</u>	<u>\$ 24.1</u>
Adjusted net income margin from continuing operations	5.4 %	5.9 %
Weighted-average shares outstanding - diluted (in thousands)	54,687	54,325
Adjusted net income per share - diluted from continuing operations (non-GAAP)	\$ 0.50	\$ 0.44
Net loss per share - diluted from continuing operations (GAAP)	\$ (1.32)	\$ (0.42)

⁽¹⁾ Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes.

⁽²⁾ Restructuring and other charges includes \$0.3 million of expense classified as Cost of sales on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023.

⁽³⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

⁽⁴⁾ Strategic transaction costs includes integration costs related to recent acquisitions and Separation-related costs.

⁽⁵⁾ The effective tax rates used to calculate adjusted net income and adjusted net income per share were 22.7% and 21.0% for the three months ended March 29, 2024 and March 31, 2023, respectively.

QTD Adjusted EBITDA Reconciliation

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)

	Three Months Ended	
	March 29, 2024	March 31, 2023
	(Dollars in millions)	
Net loss from continuing operations (GAAP)	\$ (71.8)	\$ (22.8)
Income tax benefit	(7.4)	(7.1)
Other (income) expense, net	24.2	(0.7)
Interest expense, net	20.0	5.7
Operating loss (GAAP)	(35.0)	(25.0)
Adjusted to add:		
Restructuring and other charges ⁽¹⁾	12.9	2.9
MDR and other costs ⁽²⁾	4.9	7.8
Strategic transaction costs ⁽³⁾	20.8	11.6
Stock-based compensation	6.4	6.9
Depreciation and other amortization	27.2	20.0
Amortization of acquired intangibles	40.9	32.0
Inventory step-up	5.1	0.1
Adjusted EBITDA (non-GAAP)	\$ 83.2	\$ 56.4
Adjusted EBITDA margin (non-GAAP)	16.1 %	13.9 %

⁽¹⁾ Restructuring and other charges includes \$0.3 million of expense classified as Cost of sales on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023.

⁽²⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

⁽³⁾ Strategic transaction costs includes integration costs related to recent acquisitions and Separation-related costs.

QTD Adjusted Gross Margin Reconciliation

Enovis Corporation
Reconciliation of Gross Margin (GAAP) to Adjusted Gross Margin (non-GAAP)
Dollars in millions
(Unaudited)

	Three Months Ended	
	March 29, 2024	March 31, 2023
Net sales	\$ 516.3	\$ 406.2
Gross profit	\$ 297.9	\$ 235.1
Gross profit margin (GAAP)	57.7 %	57.9 %
Gross profit (GAAP)	\$ 297.9	\$ 235.1
Inventory step-up	5.1	0.1
Restructuring and other charges	—	0.3
Adjusted gross profit (Non-GAAP)	<u>\$ 303.0</u>	<u>\$ 235.5</u>
Adjusted gross profit margin (Non-GAAP)	58.7 %	58.0 %

Q1'24 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions
(Unaudited)

	Enovis Continuing Operations	Acquisition- Related Non- Cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Income Tax Adjustment ^d	Adjusted
Net sales	\$ 516.3	\$ -	\$ -	\$ -	\$ -	\$ 516.3
Cost of goods sold	218.4	(5.1)	-	-	-	213.3
Gross profit	297.9	5.1	-	-	-	303.0
<i>Gross margin</i>	57.7%					58.7%
Selling, general and administrative expense	255.7	-	(4.9)	(27.2)	-	223.5
Research and development expense	23.4	-	-	-	-	23.4
Amortization of acquired intangibles	40.9	(40.9)	-	-	-	-
Restructuring and other charges	12.9	-	(12.9)	-	-	-
Operating (loss) income	(35.0)	46.0	17.8	27.2	-	56.1
Interest expense, net	20.0	-	-	-	-	20.0
Other expense, net	24.2	-	(24.2)	-	-	-
(Loss) income before taxes	(79.2)	46.0	42.1	27.2	-	36.1
Income tax (benefit) expense	(7.4)	-	-	-	15.6	8.2
Less: NCI income, net of taxes	0.2	-	-	-	-	0.2
Net (loss) income attributable to Enovis	\$ (72.0)	\$ 46.0	\$ 42.1	\$ 27.2	\$ (15.6)	\$ 27.7

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$20.8 and stock-based compensation expense of \$6.4.

^d The effective tax rate used to calculate adjusted net income was 22.7%.

Q1'23 GAAP to Adjusted Non-GAAP Financial Measures

Dollars in millions
(Unaudited)

	Enovis Continuing Operations	Acquisition- Related Non- Cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Income Tax Adjustment ^d	Adjusted
Net sales	\$ 406.2	\$ -	\$ -	\$ -	\$ -	\$ 406.2
Cost of goods sold	171.1	(0.1)	(0.3)	-	-	170.7
Gross profit	235.1	0.1	0.3	-	-	235.5
<i>Gross margin</i>	<i>57.9%</i>					<i>58.0%</i>
Selling, general and administrative expense	207.2	-	(7.8)	(18.5)	-	180.8
Research and development expense	18.2	-	-	-	-	18.2
Amortization of acquired intangibles	32.0	(32.0)	-	-	-	-
Restructuring and other charges	2.6	-	(2.6)	-	-	-
Operating (loss) income	(25.0)	32.2	10.7	18.5	-	36.5
Interest expense, net	5.7	-	-	-	-	5.7
Other income, net	(0.7)	-	0.7	-	-	-
(Loss) income before taxes	(30.0)	32.2	10.1	18.5	-	30.8
Income tax (benefit) expense	(7.1)	-	-	-	13.6	6.5
Less: NCI income, net of taxes	0.2	-	-	-	-	0.2
Net (loss) income attributable to Enovis	\$ (23.0)	\$ 32.2	\$ 10.1	\$ 18.5	\$ (13.6)	\$ 24.1

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$11.6 and stock-based compensation expense of \$6.9.

^d The effective tax rate used to calculate adjusted net income was 21.0%.

enovis™

Creating Better Together™